Please use this identifier to cite or link to this item:
https://scidar.kg.ac.rs/handle/123456789/8469
Title: | Synthesis and Characterization of 3-(1-((3,4-Dihydroxyphenethyl)amino)ethylidene)-chroman-2,4-dione as a Potential Antitumor Agent |
Authors: | Dimic, Dusan Marković, Zoran saso, luciano Avdović, Edina Đorović Jovanović, Jelena Petrović, Ivica Stanisavljević D. Stevanovic, Milena Potočňák I. Samoľová, Erika Trifunović, Srećko Dimitrić Marković J. |
Issue Date: | 2019 |
Abstract: | © 2019 Dušan S. Dimić et al. The newly synthesized coumarin derivative with dopamine, 3-(1-((3,4-dihydroxyphenethyl)amino)ethylidene)-chroman-2,4-dione, was completely structurally characterized by X-ray crystallography. It was shown that several types of hydrogen bonds are present, which additionally stabilize the structure. The compound was tested in vitro against different cell lines, healthy human keratinocyte HaCaT, cervical squamous cell carcinoma SiHa, breast carcinoma MCF7, and hepatocellular carcinoma HepG2. Compared to control, the new derivate showed a stronger effect on both healthy and carcinoma cell lines, with the most prominent effect on the breast carcinoma MCF7 cell line. The molecular docking study, obtained for ten different conformations of the new compound, showed its inhibitory nature against CDK S protein. Lower inhibition constant, relative to one of 4-OH-coumarine, proved stronger and more numerous interactions with CDK S protein. These interactions were carefully examined for both parent molecule and derivative and explained from a structural point of view. |
URI: | https://scidar.kg.ac.rs/handle/123456789/8469 |
Type: | article |
DOI: | 10.1155/2019/2069250 |
ISSN: | 1942-0900 |
SCOPUS: | 2-s2.0-85062271851 |
Appears in Collections: | Faculty of Science, Kragujevac Institute for Information Technologies, Kragujevac |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.1155-2019-2069250.pdf | 2.64 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License